Clinical trials: Bone Loss, Postmenopausal
Postmenopausal Osteoporosis
Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis
The main objective of this observational study was to describe medication-taking behavior of patients treated with denosumab for postmenopausal osteoporosis (PMO) at 12 and 24 months.
- Trial name
- NCT01668589
- Where
- 144 sites in Austria, Belgium and 2 more
- Volunteers
- 1,501 people
- Sponsor
- Amgen
Postmenopausal Osteoporosis
Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women
To determine the effect and safety of menatetrenone on treatment of postmenopausal osteoporosis comparing with alfacalcidol.
- Trial name
- NCT00165698
- Testing
- menatetranone, alfacalcidol
- Where
- 5 sites in China
- Volunteers
- 240 people
- Sponsor
- Eisai Co., Ltd.
Osteopenia or Osteoporosis
Effect of Consumption of Supplements and Enriched Olive Paste on Bone Metabolism Indices
It was a prospective randomized controlled trial. A sample of 115 apparently healthy post-menopausal women(45 -75 years of age) randomized into four groups and received supplements of Ca, Vitamin D and Mg with or without enriched…
- Trial name
- Osteoporosis (NCT06135831)
- Testing
- Functional olive paste, Calciovitmag (CDCaMg), Phosporovitmag (PDCaMg)
- Where
- Greece
- Volunteers
- 115 people
- Sponsor
- University of the Aegean
Postmenopausal Osteoporosis
A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)
This study is to assess the safety and tolerability of MK0217 being evaluated to treat women with postmenopausal osteoporosis.
- Trial name
- NCT00092027
- Testing
- MK0217, alendronate sodium/Duration of Treatment: 6 months
- Volunteers
- 454 people
- Sponsor
- Organon and Co
Postmenopausal Osteoporosis
A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis
This is a randomised, double-blind, multicentre study to evaluate the efficacy, safety, PK, PD, and immunogenicity of SB16 compared to Prolia® in postmenopausal women with osteoporosis.
- Trial name
- NCT04664959
- Testing
- SB16 (Proposed Denosumab Biosimilar), Prolia® (Denosumab)
- Where
- 5 sites in Poland
- Volunteers
- 457 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Perimenopausal Bone Loss
Natto Supplementation to Prevent Loss of Bone Mass in Women Immediately After Menopause
Study Objective: To determine whether Natto supplementation in women immediately after menopause might prevent severe bone loss Study population: Women 50 - 60 years, 1-5 years after menopause Study Design: Double-blind…
- Trial name
- NCT00290212
- Testing
- Natto capsules (food suppl.) cont. 360 microg. vit K2/day
- Where
- 2 sites in Norway
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- University Hospital of North Norway
Osteopenia
Study of the Effect of Once a Week Risedronate on the Microstructure of Tibia and Radius Using a New Scanning Method
The primary purpose of the protocol is to evaluate the sensitivity of 3D-pQCT (3D-Peripheral Quantitative Computed Tomography) technology to detect minute changes in bone microarchitecture.
- Trial name
- NCT00386360
- Testing
- risedronate
- Where
- 9 sites in Argentina, Australia and 5 more
- Volunteers
- 161 people
- Sponsor
- Warner Chilcott
Osteoporosis, Postmenopausal
Risedronate Sodium in Post Menopausal Osteoporosis
The primary objective is to compare subject satisfaction of once a week dosing of 35 mg Actonel to once daily dosing of 5 mg Actonel in postmenopausal osteoporotic women.
- Trial name
- NCT00453492
- Testing
- risedronate sodium
- Where
- Turkey (Türkiye)
- Volunteers
- 246 people
- Sponsor
- Sanofi
Periodontal Disease, Postmenopausal Osteoporosis (PMO)
Relationship Between Periodontal Disease and Postmenopausal Osteoporosis
Elevated sclerostin levels in serum and alveolar bone of osteoporotic patients may exert deleterious effects on the periodontium, thereby contributing to the progression and increased severity of periodontal disease.
- Trial name
- NCT07294105
- Testing
- clinical assessment, Radiographic Evaluation
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Recep Tayyip Erdogan University
Osteopenia
A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women
The primary objective of this study is to determine the safety and tolerability of AMG 167 following a single dose subcutaneous (SC) or intravenous (IV) administration in healthy men and postmenopausal women.
- Trial name
- NCT00902356
- Testing
- AMG 167
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Amgen
Osteoporosis Fracture
Height Loss, Kyphosis Indicators, Bone Mineral Density and Vertebral Fractures in Chinese Postmenopausal Women
This is an observational and cross-sectional study on the height loss, kyphosis indicators, bone mineral density and vertebral fractures in Chinese postmenopausal women
- Trial name
- NCT03798444
- Testing
- dual energy X-ray absorptiometry, lateral spine imaging from T4 to L4 on X-ray
- Where
- China
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- Central South University
Vitamin D Deficiency
Determination of Vitamin D Dose to Maintain Sufficiency Amongst Indian and Malay Women in the Tropics
Much research on vitamin D status has focused on seasonal variations in serum 25(OH)D levels in populations living at high altitudes and those of light-skinned Caucasian extraction, with little work done in multi ethnic…
- Trial name
- NCT02389179
- Testing
- Vitamin D3
- Where
- Malaysia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sharifah Faradila bt Wan Muhamad Hatta
Post-menopausal Osteoporosis
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women
This study is designed to provide information about the bone-anabolic response of PTH134 when administered orally, in comparison to Forsteo®, the sub-cutaneous form of teriparatide, the active ingredient in PTH134.
- Trial name
- NCT01224717
- Testing
- PTH134, Forsteo
- Where
- 4 sites in Denmark, Germany
- Volunteers
- 104 people
- Sponsor
- Novartis
Postmenopausal Osteoporosis
The Deferasirox-calcium-vitamin D3 Therapy for Postmenopausal Osteoporosis (PMOP)
In 2006, Weinberg proposed a hypothesis that iron accumulation was a risk factor for osteoporosis. Osteoporosis is a common complication in various diseases, such as hemochromatosis, African hemosiderosis, thalassemia, and sickle…
- Trial name
- PMOP (NCT02854722)
- Testing
- Deferasirox and calcium-vitamin D3, Calcium-vitamin D3
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital of Soochow University
Osteoporosis, Postmenopausal
The Prevalence of Osteoporotic Vertebral Compression Fractures (OVCF) in Korean Post Menopausal Women
This is an observational study to investigate the prevalence of osteoporotic fractures in post menopausal patients. Post menopausal patients who visit OS(orthopedic surgery) including GHs(general hospitals) and clinics will be…
- Trial name
- TOP (NCT01381588)
- Testing
- Fracture evaluation
- Where
- South Korea
- Volunteers
- 1,136 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Postmenopausal Peri-implant Health, Postmenopausal Peri-mucositis
Evaluation of aMMP-8 and IL-1β Levels and Marginal Bone Loss Associated With Peri-Implant Mucositis and Peri-Implantitis in Postmenopausal Women
Peri-implant mucositis and peri-implantitis are among the major biological complications threatening the long-term success of dental implants.
- Conditions
- Postmenopausal Peri-implant Health, Postmenopausal Peri-mucositis, Postmenopausal Peri-implantitis
- Trial name
- NCT07785817
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Medipol University
Osteoporosis, Postmenopausal Osteoporosis
AGE Burden and Response to Antiresorptive Therapy in Osteoporosis
Osteoporosis is a common condition that increases the risk of bone fractures. Although antiresorptive treatments such as bisphosphonates and denosumab are effective in increasing bone mineral density, some patients continue to…
- Trial name
- NCT07329543
- Volunteers
- 240 people
- Sponsor
- Bursa City Hospital
Bone Loss
The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation
The objective of the study is to demonstrate the effects that lasofoxifene has on serum markers of bone metabolism.
- Trial name
- LACE (NCT00674453)
- Testing
- Lasofoxifene
- Where
- United Kingdom
- Volunteers
- 51 people
- Sponsor
- Ligand Pharmaceuticals
Osteoporosis
Study Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal Women
The purpose of this study is to determine whether TSE-424 (bazedoxifene acetate), an investigational drug, is safe and effective in the prevention of osteoporosis in postmenopausal women.
- Trial name
- NCT00481169
- Testing
- Bazedoxifene Acetate (TSE-424)
- Volunteers
- 1,742 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Postmenopausal Osteoporosis
A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)
This study is to evaluate and compare the effects of Alendronate and Risedronate to treat women with postmenopausal osteoporosis.
- Trial name
- FACT (NCT00092014)
- Testing
- Alendronate, Risedronate 35 mg, Elemental Calcium
- Volunteers
- 1,053 people
- Sponsor
- Organon and Co